Lundbeck's schizophrenia treatment for teenagers receives FDA priority review status

Lundbeck and partner Otsuka have completed a supplemental drug application for the FDA to expand the use of schizophrenia drug Rexulti, one year earlier than expected.
Photo: Thomas Borberg
Photo: Thomas Borberg
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

In December, Lundbeck and its partner Otsuka could potentially see the indication of their treatmeant of schizophrenia, Rexulti, expanded to include an important patient group in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading